Geoff Green

Accu-Break Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The firm develops tablets that are designed to improve and enhance the functionality of pharmaceutical tablets. The company was founded in 2001 by Lawrence Solomon and David Lucking headquartered in Plantation, FL.

Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.

Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY.

Heart Genomics LLC is a biotechnology company that specializes in developing and commercializing non-invasive, genomic-based clinical diagnostic tests for patients with heart disease or heart failure. Heart Genomics is based in Miami Beach, FL. The private company's diagnostic tests provide personalized and individualized information to each patient and their physician through genomic analysis of the patient's heart tissue or blood sample. This information helps the heart patient and physician make substantially improved and clear treatment decisions. The company was founded by Paul Lehr and Joshua M. Hare, and Paul Lehr has been the CEO since incorporation.

IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS’s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. The product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments.